intismeran autogene + pembrolizumab

Intismeran autogene + Keytruda is an investigational combination immunotherapy co-developed by Moderna and Merck, integrating a personalized mRNA-based cancer vaccine with a programmed death receptor-1 (PD-1) inhibitor. Intismeran autogene (also known as mRNA-4157 or V940) is an individualized neoantigen therapy (INT) that utilizes mRNA to encode up to 34 unique tumor neoantigens identified through genomic sequencing of a patient's specific tumor. This approach aims to stimulate a robust, patient-specific T-cell response against cancer cells. Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the PD-1 checkpoint, preventing the interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor activity. The combination is currently in Phase 3 clinical development for the adjuvant treatment of high-risk resected melanoma (INTerpath-001) and non-small cell lung cancer (INTerpath-002), following positive Phase 2 results that demonstrated significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.

Other names

intismeranpembrolizumabmRNA-4157 + pembrolizumabV940 + pembrolizumab